Merck obtains rights to market seasonal influenza vaccine
Afluria
Agreement with CSL Biotherapies will allow company to market and
distribute vaccine for 2010/2011 through 2015/2016 influenza
seasons.
Merck & Co., Inc., announced on September 28 that an
exclusive agreement with CSL Biotherapies will allow Merck to
market and distribute the seasonal influenza vaccine Afluria, beginning
with the 2010/2011 influenza season and continuing through the 2015/2016
season.
The terms of the agreement stipulate that Merck will have control of
commercialization of Afluria in the United States and that CSL will
supply Afluria to Merck and retain marketing rights for the vaccine
outside of the United States.
Approved by FDA in September 2007, Afluria is indicated for the
active immunization of patients 18 years of age or older against
influenza disease caused by influenza virus subtypes A and type B
present in the vaccine.
Source
Joe Sheffer (jsheffer@aphanet.org)
Posted September 28, 2009
|
